Emerging therapies for small cell lung cancer

Currently, chemotherapy remains the standard treatment for first- and second-line management of small cell lung cancer (SCLC). Immunotherapy has made progress in the treatment of SCLC, and nivolumab, pembrolizumab, atezolizumab, and durvalumab have led to significant improvements in clinical outcome...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of hematology and oncology Ročník 12; číslo 1; s. 47 - 11
Hlavní autoři: Yang, Sen, Zhang, Zhe, Wang, Qiming
Médium: Journal Article
Jazyk:angličtina
Vydáno: London BioMed Central 02.05.2019
BioMed Central Ltd
Springer Nature B.V
BMC
Témata:
Antineoplastic Combined Chemotherapy Protocols - pharmacology
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer Research
Cancer therapies
Cancer treatment
Carboplatin
Care and treatment
Chemotherapy
Clinical trials
Cytotoxicity
Drug dosages
Hematology
Humans
Immunotherapy
Immunotherapy - methods
Ipilimumab
Lung cancer
Lung Neoplasms - drug therapy
Lung Neoplasms - pathology
Medical prognosis
Medicine
Medicine & Public Health
Metastasis
Methods
Monoclonal antibodies
Neutropenia
Oncology
Orphan drugs
Pembrolizumab
Review
RNA polymerase
Small cell lung cancer
Small cell lung carcinoma
Small Cell Lung Carcinoma - drug therapy
Small Cell Lung Carcinoma - pathology
Targeted cancer therapy
Targeted therapy
China
Small cell lung cancer
Chemotherapy
Targeted therapy
Immunotherapy
ISSN:1756-8722, 1756-8722
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Currently, chemotherapy remains the standard treatment for first- and second-line management of small cell lung cancer (SCLC). Immunotherapy has made progress in the treatment of SCLC, and nivolumab, pembrolizumab, atezolizumab, and durvalumab have led to significant improvements in clinical outcomes of SCLC. Regarding options in other classes of therapy, the cytotoxic drug lurbinectedin was granted orphan drug status based on a remarkable objective response rate of 39.3%. In addition, an increase in progression-free survival (PFS) was achieved in a phase II study of anlotinib (ALTER 1202). Future prospects for even better outcomes in SCLC lie in novel ways to integrate immunotherapy and small-molecule TKI drugs. Innovative clinical trial designs are needed to efficiently explore the increasing number of options with new drugs and new combinations thereof for SCLC.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1756-8722
1756-8722
DOI:10.1186/s13045-019-0736-3